Pulmonary Hypertension

Finding Balance Between Living to the Fullest and Taking Precautions - Pulmonary Hypertension News Finding Balance Between Living to the Fullest and Taking Precautions - Pulmonary Hypertension News Posted: 21 Feb 2020 12:00 AM PST Recently, it seems that all we hear about is the coronavirus . Between that and the cold or flu that many are dealing with, I must take preventive measures. But how many measures can I take while still living a somewhat normal life? I've noticed that others tend to go to the extreme with this. Living with a life-threatening illness like pulmonary hypertension (PH) means that I must take precautions all the time, not only when an outbreak of the newest superbug occurs. Because of PH and my coexisting illnesses, I have a compromised immune system. Despite this, I want to live my life as "normally" as possible. For me, this may mean that I take extra vitamins. Or th...

Specific gut bacteria may be associated with pulmonary arterial hypertension - Science Daily Specific gut bacteria may be associated with pulmonary arterial hypertension - Science Daily Posted: 24 Feb 2020 04:54 AM PST Researchers have identified a distinct collection of bacteria found in the gut that may contribute to and predict the development of pulmonary arterial hypertension (PAH), according to new research published today in the American Heart Association's journal Hypertension . PAH is a chronic and progressive disease in which the arteries that supply blood to the lungs are constricted, resulting in symptoms such as shortness of breath, heart palpitations, fatigue and others. In PAH, persistently high blood pressure in lung arteries makes the right side of the heart work too hard to pump blood, resulting in right-sided heart failure (inability of the heart to pump blood adequately). It is much less common than systemic blood pre...

Noticing the Subtle Signs of Pulmonary Hypertension - Pulmonary Hypertension News Noticing the Subtle Signs of Pulmonary Hypertension - Pulmonary Hypertension News Posted: 21 Feb 2020 12:00 AM PST For most of my life, my illnesses were invisible. I could walk into a public place and not expect sideways glances or stares. I didn't feel like a fish out of water. The only difference between my friends and me was the scar down the middle of my chest. I had athleticism, stamina, and could skate my way across a hockey rink. But after a few years of living with pulmonary hypertension (PH), the invisible became visible . I have a nasal cannula, a backpack with supplemental oxygen , a BiPAP   machine, a pale complexion from anemia, and dark circles under my eyes. The first thing most people notice is the cannula. With it, no one questions me when I park in a handicapped-accessible space. It also acts as a...

Inhalation therapy shows promise against pulmonary fibrosis in mice, rats - Science Daily Inhalation therapy shows promise against pulmonary fibrosis in mice, rats - Science Daily Posted: 28 Feb 2020 01:56 AM PST A new study from North Carolina State University shows that lung stem cell secretions -- specifically exosomes and secretomes -- delivered via nebulizer, can help repair lung injuries due to multiple types of pulmonary fibrosis in mice and rats. The work could lead to more effective, less invasive treatment for human pulmonary fibrosis sufferers. Pulmonary fibrosis is a fatal disease that thickens and scars healthy lung tissue, creating inflammation and replacing the lining of the lung cells with fibrotic tissue. In the last five years, Ke Cheng and his lab developed spheroid-produced lung stem cells (LSCs) as a potential therapeutic for pulmonary fibrosis. Cheng is the Randall B. Terry Jr. Distinguished Professor in Regenerative Me...

Orenitram Slows PAH Progression When Used With Other Therapies... - Pulmonary Hypertension News Orenitram Slows PAH Progression When Used With Other Therapies... - Pulmonary Hypertension News Posted: 13 Jan 2020 12:00 AM PST Orenitram ( treprostinil tablets) reduced clinical worsening and slowed disease progression in people with pulmonary arterial hypertension (PAH) who had recently begun treatment with an alternative approved therapy, a Phase 3 clinical trial has found. Trial findings were reported in the study, " Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension: A Double-Blind, Placebo-Controlled Study ," published in the American Journal of Respiratory and Critical Care Medicine . Orenitram , marketed by United Therapeutics , is an approved , extended-release oral formulation of Remodulin (treprostinil injection), which has been shown to improve exercise ab...

Specific gut bacteria may be associated with pulmonary arterial hypertension - Science Daily Specific gut bacteria may be associated with pulmonary arterial hypertension - Science Daily Posted: 24 Feb 2020 04:54 AM PST Researchers have identified a distinct collection of bacteria found in the gut that may contribute to and predict the development of pulmonary arterial hypertension (PAH), according to new research published today in the American Heart Association's journal Hypertension . PAH is a chronic and progressive disease in which the arteries that supply blood to the lungs are constricted, resulting in symptoms such as shortness of breath, heart palpitations, fatigue and others. In PAH, persistently high blood pressure in lung arteries makes the right side of the heart work too hard to pump blood, resulting in right-sided heart failure (inability of the heart to pump blood adequately). It is much less common than systemic blood pre...

Case Report Suggests Lack of Vitamin C as PAH Cause - Pulmonary Hypertension News Case Report Suggests Lack of Vitamin C as PAH Cause - Pulmonary Hypertension News Posted: 17 Feb 2020 12:00 AM PST Vitamin C deficiency can cause pulmonary arterial hypertension (PAH), a new case report suggests, highlighting the need to test vitamin C levels in people with PAH. The report, " Vitamin C Deficiency-Induced Pulmonary Arterial Hypertension ," was published in the journal  CHEST . The study details the case of a man in his 60s with a history of systemic high blood pressure ( hypertension ), and difficulty breathing after exertion. The patient was hospitalized due to systemic hypertensive urgency  — dangerously high blood pressure throughout the body, without an obvious cause or organ damage. Right heart catheterization revealed a pulmonary artery systolic pressure of 72 mm Hg (normal range 18–25 mm...

Aria CV Pulmonary Hypertension Acquires $31 Million for Feasibility Study - Diagnostic and Interventional Cardiology Aria CV Pulmonary Hypertension Acquires $31 Million for Feasibility Study - Diagnostic and Interventional Cardiology Posted: 27 Feb 2020 11:43 AM PST February 27, 2020 — Aria CV Inc. completed a $31 million Series B round of financing to fund its first clinical study in the United States for an implantable device to treat pulmonary arterial hypertension (PAH).  The funding will support an U.S. Food and Drug Administration (FDA) early feasibility investigational study designed to evaluate long term implants of the Aria CV Pulmonary Hypertension System (Aria CV PH System) in PAH patients. The Series B funding close comes just one week after the Aria CV PH System was granted Breakthrough Device Designation by the FDA , which is intended to expedite the FDA review and approval of designated devices that may provide more effective ...

PhaseBio Announces Case Study Highlighting PB1046 Hemodynamic Data Presented at the 14th Pulmonary Vascular Research Institute World Congress - Yahoo Finance PhaseBio Announces Case Study Highlighting PB1046 Hemodynamic Data Presented at the 14th Pulmonary Vascular Research Institute World Congress - Yahoo Finance Posted: 04 Feb 2020 12:00 AM PST Data continue to support potential of once-weekly VIP analogue for adults with pulmonary arterial hypertension MALVERN, Pa. and SAN DIEGO, Calif., Feb. 04, 2020 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. ( PHAS ), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced presentation of data from a patient who received more than 18 months of treatment with PB1046, the company's first-in-class, sustained-release vasoactive intestinal peptide (VIP) analogue being evaluated for the treatment o...